Pharmacological therapy for proliferative vitreoretinopathy.
We developed an animal model in the rabbit eye with intravitreally injected heterotransplanted bovine retinal pigment epithelial cells to test a pharmacological agent which would reduce extracellular matrix formation. Results with 20 and 60 micrograms of cis-hydroxyproline showed a 48% decrease in the rate of traction retinal detachments.
Radtke
N D
ND
Weinsieder
A D
AD
Ballou
R J
RJ
D000818:Animals; D002417:Cattle; D003094:Collagen / Q000378:metabolism; D005109:Extracellular Matrix / Q000378:metabolism; D005128:Eye Diseases / Q000150:complications / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D006909:Hydroxyproline / Q000627:therapeutic use*; D008297:Male; D013508:Ophthalmologic Surgical Procedures; D010857:Pigment Epithelium of Eye / Q000166:cytology / Q000637:transplantation; D011817:Rabbits; D012163:Retinal Detachment / Q000517:prevention & control; D012164:Retinal Diseases / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D013237:Stereoisomerism; D014822:Vitreous Body / Q000187:drug effects / Q000648:ultrastructure
D003094:Collagen; D006909:Hydroxyproline